1. Referências Bibliográficas:
1.
BIBLIOTECA Virtual em Saúde. DeCS – Descritores em Ciências da Saúde. Disponível em:
<http://www.decs.bvs.br>. Acesso em 28 abr 2011.
2.
MOREIRA, Rodrigo O et al . Perfil lipídico de pacientes com alto risco para eventos cardiovasculares na
prática clínica diária. Arq Bras Endocrinol Metab. 2006 Jun ; 50(3): 481‐489. Disponível em:
<http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004‐27302006000300011&lng=pt>. Acesso em 28 abr
2011.
3.
SPOSITO, Andrei C. et al. Sociedade Brasileira de Cardiologia. IV Brazilian Guideline for dyslipidemia and
atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology. Arq Bras Cardiol.
2007;88(supl 1):2‐19.
4.
SOCIEDADE Brasileira de Cardiologia. Prevenção da arterosclerose ‐ Dislipidemia. Projeto Diretrizes, 2001.
Disponível em:<http://www.projetodiretrizes.org.br/projeto_diretrizes/040.pdf>. Acesso em 02 ago 2011.
5.
OLIVEIRA, Ticihana Ribeiro de et al . Fatores associados à dislipidemia na pós‐menopausa. Rev. Bras.
Ginecol. Obstet., Rio de Janeiro, v. 30, n. 12, dez. 2008 . Disponível em
<http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100‐72032008001200002&lng=pt&nrm=iso>. Acesso em
02 ago 2011.
6.
GEPNER, A. D. et al. Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a
randomized clinical trial. Am Heart J. 2011 Jan;161(1):145‐51.
7.
CERVATO, Ana Maria et al . Dieta habitual e fatores de risco para doenças cardiovasculares. Rev. Saúde
Pública, São Paulo, v. 31, n. 3, Jun 1997. Disponível em:
<http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034‐89101997000300003&lng=en&nrm=iso>. Acesso
em 02 ago 2011
8.
GUIMARÃES, A.C. et al. The cholesterol level of a selected Brazilian salaried population: biological and
socioeconomic influences. CVD Prevention. 1998;1:306‐17 apud SPOSITO, Andrei C. et al. Sociedade Brasileira de
Cardiologia. IV Brazilian Guideline for dyslipidemia and atherosclerosis prevention: Department of Atherosclerosis of
Brazilian Society of Cardiology. Arq Bras Cardiol. 2007;88(supl 1):2‐19.
9.
BRASIL. Ministério da Saúde. Secretaria de Atenção à Saúde. Portaria nº 1.015 de 23 de Dezembro de
2002. Dispõe o Protocolo clínico e Diretrizes Terapêuticas. Dislipidemias em pacientes de alto risco de desenvolver
eventos cardiovasculares. Brasília: 2002. Disponível em:
<http://dtr2001.saude.gov.br/sas/dsra/protocolos/index.htm>. Acesso em 03 ago 2011
10.
Consulta Pública nº 42, de 16 de dezembro de 2010. Dispõe em consulta pública o Protocolo Clínico e
Diretrizes Terapêuticas – Dislipidemia – prevenção de eventos cardiovasculares e pancreatite. Brasília: 2010.
Disponível em: <http://portal.saude.gov.br/portal/arquivos/pdf/cp_42_dislipidemia_2010_.pdf>. Acesso em 03 ago
2011.
11.
AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Estatinas na prevenção primária de eventos
cardiovasculares. Boletim Brasileiro de Avaliação de Tecnologias em Saúde (BRATS). Brasília, 2009, set, Ano IV, n.9.

2. 12.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian.
Simvastatin Survival Study (4S). Lancet 1994 Nov 19;344(8934):1383‐9.
13.
HEART Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with
simvastatin in 20.536 high‐risk individuals: a randomised placebo‐controlled trial. Lancet 2002 Jul 6;360(9326):7‐22.
14.
SACKS, Frank M. et al. The effect of pravastatin on coronary events after myocardial infarction in patients
with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996 Oct
3;335(14):1001‐9.
15.
THE LONG‐TERM Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of
cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial
cholesterol levels. N Engl J Med 1998 Nov 5;339(19):1349‐57.
16.
SEVER, P.S. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who
have average or lower‐than‐average cholesterol concentrations, in the Anglo‐Scandinavian Cardiac Outcomes Trial‐‐
Lipid Lowering Arm (ASCOT‐LLA): a multicentre randomised controlled trial. Lancet 2003 Apr 5;361(9364):1149‐58.
17.
CANNON, Christophe P et al. Intensive versus moderate lipid lowering with statins after acute coronary
syndromes. N Engl J Med 2004 Apr 8;350(15):1495‐504.
18.
LAROSA, John C. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N
Engl J Med 2005 Apr 7;352(14):1425‐35
19.
DOWNS, J.R. et al. Primary prevention of acute coronary events with lovastatin in men and women with
average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
JAMA 1998 May 27;279(20):1615‐22.
20.
RIDKER, P.M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive
protein. N Engl J Med 2008 Nov 20;359(21):2195‐207.
21.
TAYLOR, Fiona, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of
Systematic Reviews. In: The Cochrane Library, Issue 07, Art. No. CD004816. DOI:
10.1002/14651858.CD004816.pub1.
22.
DE CATERINA R, et al. Cholesterol‐lowering interventions and stroke: insights from a meta‐analysis of
randomized controlled trials. J Am Coll Cardiol. 2010 Jan 19;55(3):198‐211.
23.
MILLS, E. J. Efficacy and safety of statin treatment for cardiovascular disease: a network meta‐analysis of 170
255 patients from 76 randomized trials. QJM. 2011 Feb;104(2):109‐24. Epub 2010 Oct 7.
24.
AUSTRALIAN GOVERNEMENT. DEPARTAMENT OF HEALTH AND AGEING. General statement for lipid‐
lowering drugs prescribed as pharmaceutical benefits. Disponível em:
<http://www.pbs.gov.au/info/healthpro/explanatory‐notes/gs‐lipid‐lowering‐drugs>. Acesso em 04 ago 2011.
25.
NATIONAL INSTITUTO FOR HEALTH AND CLINICAL EXCELLENCE. Statins for the prevention of cardiovascular
events in patients at increased risk of developing cardiovascular disease or those with established cardiovascular
disease. Technology appraisals TA94, Londres, 2006 Jan.